关注
Joshua S. Bryer
Joshua S. Bryer
Manager of Research Projects, University of Pennsylvania
在 pennmedicine.upenn.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Renal compartment–specific genetic variation analyses identify new pathways in chronic kidney disease
C Qiu, S Huang, J Park, YS Park, YA Ko, MJ Seasock, JS Bryer, XX Xu, ...
Nature medicine 24 (11), 1721-1731, 2018
1952018
Monkeypox emerges on a global scale: a historical review and dermatologic primer
J Bryer, EE Freeman, M Rosenbach
Journal of the American Academy of Dermatology 87 (5), 1069-1074, 2022
682022
Granulomatous dermatitis associated with rubella virus infection in an adult with immunodeficiency
BE Shields, L Perelygina, S Samimi, P Haun, T Leung, E Abernathy, ...
JAMA dermatology 157 (7), 842-847, 2021
202021
Screening drugs for kidney disease: targeting the podocyte
JS Bryer, K Susztak
Cell Chemical Biology 25 (2), 126-127, 2018
162018
Responsiveness to change and establishment of the minimal clinically important difference for the cutaneous sarcoidosis activity and morphology instrument
MH Noe, JM Gelfand, JS Bryer, SN Price, MA Judson, M Rosenbach
JAMA dermatology 156 (1), 98-99, 2020
102020
Monkeypox emerges on a global scale: A historical review and dermatologic primer
JS Bryer, EE Freeman, M Rosenbach
Journal of the American Academy of Dermatology 88 (5), e259, 2023
52023
A Phase 1 trial of targeted DSG3-CAART cell therapy in mucosal-dominant pemphigus vulgaris (mPV) patients: early cohort data
DJ Chang, S Basu, D Porter, M Abedi, WK Weng, R Micheletti, ...
MOLECULAR THERAPY 30 (4), 373-373, 2022
32022
Identification of a neutrophil-specific PIK3R1 mutation facilitates targeted treatment in a patient with Sweet syndrome
S Bhattacharya, S Basu, E Sheng, C Murphy, J Wei, AE Kersh, CA Nelson, ...
The Journal of Clinical Investigation 133 (1), 2023
22023
A prospective comparison of cutaneous sarcoidosis disease response to immunomodulatory and immunosuppressive therapies
P Sharma, JS Bryer, S Price, MH Noe, M Rosenbach
Journal of the American Academy of Dermatology 82 (6), 1546-1548, 2020
12020
1548 Identification of a neutrophil-specific PIK3R1 mutation facilitates targeted treatment in a patient with sweet syndrome
S Bhattacharya, S Basu, E Sheng, J Wei, A Kersh, C Nelson, J Bryer, ...
Journal of Investigative Dermatology 143 (5), S266, 2023
2023
Penicillin allergy evaluation in hospitalized patients with hematologic malignancy
VM Patel, B Chu, KW Hamilton, C Bellamy, C Harker, JS Bryer, B Shields, ...
Antimicrobial Stewardship & Healthcare Epidemiology 3 (1), e92, 2023
2023
LB1040 Treatment of sweet syndrome by molecular identification of PIK3R1 mutation
S Bhattacharya, E Sheng, C Murphy, J Wei, A Kersh, C Nelson, J Bryer, ...
Journal of Investigative Dermatology 142 (8), B37, 2022
2022
P171 IMPLEMENTATION OF A PENICILLIN SKIN TESTING SERVICE IN INPATIENTS WITH HEMATOLOGIC MALIGNANCIES
B Chu, V Patel, J Bryer, K Hamilton, O Fadugba, R Micheletti
Annals of Allergy, Asthma & Immunology 127 (5), S49-S50, 2021
2021
A Phase 1 trial of desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) for targeted B cell depletion in patients with mucosal-dominant pemphigus vulgaris: The …
E Maverakis, RG Micheletti, DL Porter, M Abedi, L Downing, JS Bryer, ...
系统目前无法执行此操作,请稍后再试。
文章 1–14